

10/590,694

=> file caplus

FILE 'CAPLUS' ENTERED AT 10:29:39 ON 01 MAY 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 1 May 2008 VOL 148 ISS 18


FILE LAST UPDATED: 30 Apr 2008 (20080430/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> d que

L1 STR



Structure attributes must be viewed using STN Express query preparation.

L3 62 SEA FILE=REGISTRY SSS FUL L1

L4 926 SEA FILE=CAPLUS L3

L5 244 SEA FILE=CAPLUS L4 AND SODIUM

L6 3 SEA FILE=CAPLUS L5 AND AMORPHOUS

=> d l6 1-3 ibib abs hitstr

L6 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:979660 CAPLUS

DOCUMENT NUMBER: 143:292525

TITLE: Amorphous forms of risedronate monosodium

INVENTOR(S): Richer, Jindrich; Jirman, Josef; Petrickova, Hana

PATENT ASSIGNEE(S): Zentiva, A.S., Czech Rep.


SOURCE: PCT Int. Appl., 28 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005082915	A1	20050909	WO 2005-CZ24	20050228
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CZ 298383	B6	20070912	CZ 2004-292	20040226
CZ 298328	B6	20070829	CZ 2004-798	20040708
CZ 298491	B6	20071017	CZ 2004-880	20040812
EP 1723157	A1	20061122	EP 2005-706666	20050228
EP 1723157	B1	20071128		
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV, YU				
US 20070142332	A1	20070621	US 2006-590694	20060825
PRIORITY APPLN. INFO.:			CZ 2004-292	A 20040226
			CZ 2004-798	A 20040708
			CZ 2004-880	A 20040812
			WO 2005-CZ24	W 20050228
AB	The monosodium salt of 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonic acid in new amorphous forms, methods of preparation and a pharmaceutical formulation are disclosed. The amorphous form of risedronate sodium was prepared by drying risedronate pentahydrate at 130° for 5h.			
IT	115436-72-1 RL: FMU (Formation, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); FORM (Formation, nonpreparative); USES (Uses) (amorphous forms of risedronate monosodium)			
RN	115436-72-1 CAPLUS			
CN	Phosphonic acid, P,P'-[1-hydroxy-2-(3-pyridinyl)ethylidene]bis-, sodium salt (1:1) (CA INDEX NAME)			




● Na

IT 864160-10-1, Risedronate pentahydrate
 RL: PEP (Physical, engineering or chemical process); PYP (Physical

process); PROC (Process)
(amorphous forms of risedronate monosodium)

RN 864160-10-1 CAPLUS

CN Phosphonic acid, [1-hydroxy-2-(3-pyridinyl)ethylidene]bis-, pentahydrate
(9CI) (CA INDEX NAME)



● 5 H₂O

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:975633 CAPLUS

DOCUMENT NUMBER: 143:272509

TITLE: Preparation of amorphous
3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonic acid
monosodium salt (sodium risedronate)

INVENTOR(S): Turchetta, Stefano; Massardo, Pietro; Ciambecchini,
Umberto

PATENT ASSIGNEE(S): Chemi S.P.A., Italy

SOURCE: Eur. Pat. Appl., 9 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1571152	A1	20050907	EP 2005-101211	20050218
EP 1571152	B1	20070808		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
ES 2289650	T3	20080201	ES 2005-101211	20050218
CA 2498177	A1	20050903	CA 2005-2498177	20050224
US 20050215793	A1	20050929	US 2005-68484	20050228
PRIORITY APPLN. INFO.:			IT 2004-MI403	A 20040303
			US 2004-558908P	P 20040401

AB A process for the preparation of sodium risedronate in an amorphous form, preferably lyophilized, and its pharmaceutical compns. are described. The amorphous form, characterized by stability and simplicity of preparation and formulation, can be obtained by an industrially applicable lyophilization process, which comprises the steps of: dissolving or suspending risedronic acid in an aqueous solvent, adding one equivalent of a base having sodium as the cation and subjecting the solution to lyophilization. Thus, lyophilized sodium risedronate was mixed with lactose and Mg stearate to give tablets.


10/590,694

IT 115436-72-1P, Sodium risedronate
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amorphous sodium risedronate)
RN 115436-72-1 CAPLUS
CN Phosphonic acid, P,P'-[1-hydroxy-2-(3-pyridinyl)ethylidene]bis-, sodium
salt (1:1) (CA INDEX NAME)



● Na

IT 105462-24-6, Risedronic acid
RL: RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT
(Reactant or reagent); USES (Uses)
(preparation of amorphous sodium risedronate)
RN 105462-24-6 CAPLUS
CN Phosphonic acid, P,P'-[1-hydroxy-2-(3-pyridinyl)ethylidene]bis- (CA INDEX
NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:612312 CAPLUS
DOCUMENT NUMBER: 143:97528
TITLE: An improved process for the preparation of alkyl- and
aryl-substituted α -hydroxy-1,1-
ethanediphosphonic acids and salts thereof by
solvent-free reaction of carboxylic acids with
phosphorous acid and phosphorus oxychloride
INVENTOR(S): Grassi, Simona; Volante, Anna
PATENT ASSIGNEE(S): Lyogen Limited, Cyprus
SOURCE: PCT Int. Appl., 9 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

WO 2005063779	A2	20050714	WO 2004-EP14556	20041222
WO 2005063779	A3	20050929		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2551230	A1	20050714	CA 2004-2551230	20041222
EP 1716161	A2	20061102	EP 2004-804152	20041222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
US 20070112197	A1	20070517	US 2006-584022	20061025
PRIORITY APPLN. INFO.:				
			IT 2003-MI2582	A 20031223
			IT 2004-MI80	A 20040122
			WO 2004-EP14556	W 20041222

OTHER SOURCE(S): CASREACT 143:97528; MARPAT 143:97528

AB α -Hydroxy-1,1-ethanediphosphonic acids R(CH₂)_mC(OH)[PO(OH)₂]₂ [m = 1-8; R = dialkylamino or 5- or 6-membered (hetero)aryl, preferably imidazolyl and pyridinyl], preferably risedronic, zoledronic and ibandronic acids, useful in therapy as inhibitors of bone reabsorption (no data) were prepared by reaction carboxylic acids R(CH₂)_mCOOH (same m, R) with 2-4 equiv of POCl₃ and 8-12 equiv of H₃PO₃, preferably the carboxylic acid:POCl₃:H₃PO₃ ratio is 1:3:10. In an example, addition of 0.19 mol of POCl₃ to a mixture of 0.06 mol of (3-pyridinyl)acetic acid and 0.58 mol of H₃PO₃ followed by stirring at 60-70° for 24 h with subsequent aqueous work-up gave 1-hydroxy-2-(3-pyridinyl)-1,1-ethanediphosphonic acid (risedronic acid) in 60% yield. Amorphous monosodium salt of 1-hydroxy-2-[(methyl)(pentyl)amino]-1,1-1,1-ethanediphosphonic acid (monosodium ibandronate), useful in the pharmaceutical use due of its increased bioavailability (no data) was prepared by neutralization of 10 g of analogously prepared ibandronic acid in 200 mL of water by 1M NaOH to pH 4.3-4.4 and lyophilization of the resulting solution


IT 105462-24-6P, Risedronic acid

RL: SPN (Synthetic preparation); PREP (Preparation)

(improved process for preparation of α -hydroxy-1,1-ethanediphosphonic acids by solvent-free phosphonation of carboxylic acids by phosphorous acid and phosphorus oxychloride)

RN 105462-24-6 CAPLUS

CN Phosphonic acid, P,P'-[1-hydroxy-2-(3-pyridinyl)ethylidene]bis- (CA INDEX NAME)



=>